Objective-Platelet hyperactivity is a contributing factor in the pathogenesis of cardiovascular disease and can be induced by elevated levels of circulating growth factors, such as insulin-like growth factor-1 (IGF-1). IGF-1 is a primer that cannot stimulate platelet activation by itself, but in combination with physiological stimuli can potentiate platelet functional responses via a phosphoinositide 3-kinase-dependent mechanism. In this study, we explored the role of the phosphoinositide 3-kinase p110α isoform in IGF-1-mediated enhancement of platelet function. Approach and Results-Using a platelet-specific p110α knockout murine model, we demonstrate that genetic deletion, similar to pharmacological inactivation of p110α, did not affect proteinase-activated receptor 4 signaling to Akt/protein kinase B but significantly reduced IGF-1-mediated Akt phosphorylation. The p110β inhibitor TGX-221 abolished IGF-1-induced Akt phosphorylation in p110α-deficient platelets, demonstrating that both p110α and p110β contribute to IGF-1-mediated Akt phosphorylation. Genetic deletion of p110α had no effect on IGF-1-mediated increases in thrombus formation on collagen and enhancement of proteinase-activated receptor 4-mediated integrin activation and α-granule secretion. In contrast, pharmacological inhibition of p110α blocked IGF-1-mediated potentiation of integrin activation and α-granule secretion. Functional enhancement by IGF-1 in p110α knockout samples was lost after TGX-221 treatment, suggesting that p110β drives priming in the absence of the p110α isoform. Conclusions-Together, these results demonstrate that both p110α and p110β are involved in Akt signaling by IGF-1, but that it is the p110α isoform that is responsible for IGF-1-mediated potentiation of platelet function. (Arterioscler Thromb Vasc Biol. 2014;34:1681-1688 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
U nder physiological conditions, platelets circulate in the vasculature in a quiescent state. On encountering a site of vascular injury, platelets adhere to the newly exposed extracellular matrix proteins, collagen and von Willebrand factor. Subsequent activation of platelets results in rapid spreading, activation of integrin α IIb β 3 , and secretion of dense and α-granule content, which in turn promotes platelet aggregation and thrombus formation. Platelet degranulation also results in the release of various autocrine agonists that induce platelet activation, as well as various growth factors that are contained within the α granules, including insulin-like growth factor-1 (IGF-1), platelet-derived growth factor, and transforming growth factor-β. [1] [2] [3] [4] IGF-1 alone is unable to activate platelets, but in combination with activating stimuli potentiates various platelet functional responses. [5] [6] [7] IGF-1 is a peptide hormone that mediates its function by binding to the transmembrane IGF-1 receptor, which is highly expressed on the platelet plasma membrane 8, 9 and in a wide variety of other tissues. The receptor shares a high degree of homology with the insulin receptor, with recent studies demonstrating the ability of IGF-1 to signal via IGF-1/insulin hybrid receptors in platelets. 9 Both receptors belong to the subclass II tyrosine kinase receptor superfamily and exist in a heterodimeric conformation composed of 2 αβ subunits linked by disulfide bridges. Binding of IGF-1 to the IGF-1 receptor induces transautophosphorylation and activation of the β subunits, 10 resulting in the recruitment and phosphorylation of the insulin receptor substrate (IRS) proteins IRS-1 and IRS-2. 6 Tyrosine phosphorylation of IRS proteins creates docking sites for the regulatory p85 subunit of phosphoinositide 3-kinase (PI3K), leading to the recruitment of the PI3K enzymes to their membrane-bound substrates.
PI3K has been shown to be important in primer-mediated enhancement of platelet function. 6, 11, 12 Activation of PI3K leads to the conversion of phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphosphate via the addition of a phosphate group to the D3 position of the phosphatidylinositol-4,5-bisphosphate inositol ring. Phosphatidylinositol-3,4,5trisphosphate accumulation at the membrane triggers the recruitment of pleckstrin homology domain-containing proteins, which are likely to be involved in the potentiating effect of primers on platelet function. 6, 11, 12 One such protein, protein kinase B (Akt), becomes phosphorylated on Thr 308 on recruitment, with subsequent phosphorylation of Ser 473 resulting in maximal Akt activity. 13 The role of Akt in primer-mediated platelet potentiation has not yet been firmly established.
Platelets express all class I PI3Ks, which are further subdivided into class IA kinases (comprising the p110α, p110β, and p110δ isoforms) and the class IB kinase p110γ. 14, 15 Pharmacological and genetic approaches have indicated that p110β plays a dominant role in Akt activation and various platelet functional responses, particularly downstream of glycoprotein VI and the integrin α IIb β 3. [16] [17] [18] [19] In contrast, a cooperative signaling function between p110β and p110γ contributes to ADP-mediated platelet function downstream of the P2Y12 receptor. 20 The p110δ isoform has been shown to play a relatively minor role in platelet activation, a trait that is likely attributed to its low levels of expression. 21 Recent studies using isoform-selective inhibitors implied that p110α may contribute to thrombus formation 19, 22 and IGF-1-mediated potentiation of platelet function. 6, 7 Platelets play a critical role in hemostasis and have been implicated in the pathogenesis of cardiovascular disease. 23 Interestingly, platelet primers such as IGF-1 are able to modulate platelet function, and altered levels of such primers may contribute to the development of cardiovascular disease. 24 Therefore, it is important to define the intracellular mechanisms involved in physiological primer-mediated platelet responses. In this study, we used a newly generated p110α conditional knockout mouse model in conjunction with PI3K isoform-selective inhibitors to address the role of PI3K isoforms in IGF-1-mediated Akt phosphorylation and platelet priming. Our findings demonstrate that (1) both the p110α and p110β PI3K isoforms contribute to IGF-1mediated Akt phosphorylation, but only the p110α isoform is critical for IGF-1-mediated priming; and (2) deletion of the p110α isoform allows IGF-1-mediated priming to be driven through p110β.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Genetic Deletion of the p110α Catalytic Subunit in Platelets
To evaluate the role of p110α in platelet function and priming, we generated conditional p110α-deficient mice. To achieve this, the coding sequence of exons 18 and 19 in the kinase domain of p110α was deleted by Cre-mediated excision. Western blotting of p110α flox/flox :Pf4-Cre − (wild type [WT]) and p110α flox/flox :Pf4-Cre + (knockout [KO]) platelet lysates confirmed that p110α was absent in KO platelets ( Figure 1A ). The loss of p110α did not result in alterations in the expression levels of the other class I PI3K isoforms (p110β, p110δ, and p110γ) or in the regulatory subunit p85 ( Figure 1A ). Furthermore immunoprecipitation of p85 from p110α KO platelets demonstrated that the basal association of p85 with p110β and p110δ was comparable with that observed in WT platelets ( Figure 1A ). Blood counts ( Table I in the online-only Data Supplement) and platelet surface expression of integrin αIIb, glycoprotein VI, integrin α2 (CD49b), and GP1bα (glycoprotein 1bα; CD42b) were also unchanged in p110α KO mice ( Figure 1B ). We thus successfully generated a conditional p110α KO mouse, which demonstrates normal platelet expression of various PI3K subunits and key surface receptors.
Deletion of p110α Results in a Reduction in IGF-1-Mediated But Not PAR4-Mediated Akt Phosphorylation
Previous mouse studies have reported an essential role for p110β in glycoprotein VI-and proteinase-activated receptor 4 (PAR4)-mediated Akt phosphorylation. 16, 18 To evaluate the role of p110α in Akt phosphorylation downstream of PAR receptors, we stimulated murine platelets with the synthetic PAR4activating peptide, PAR4-AP. Deletion of p110α had no effect on phosphorylation of Akt at Ser 473 or Thr 308 induced by a range of agonist doses ( Figure 2A stimulation ( Figure 2B ), suggesting that p110α does not contribute to PAR-mediated Akt phosphorylation. We and others previously found that IGF-1-stimulated Akt phosphorylation in human platelets was ablated on pretreatment with the p110α inhibitor PIK-75. 6, 7 Here, we find that IGF-1 also stimulates a dose-dependent increase in Akt phosphorylation in mouse platelets ( Figure 2C ), reaching maximal phosphorylation at 5 minutes ( Figure 2D ). Loss of p110α significantly reduced, but did not block, IGF-1-mediated Akt phosphorylation ( Figure 2C and 2D). Together, these results demonstrate that p110α contributes to Akt phosphorylation by IGF-1 but not by PAR4-AP.
Agonist-Stimulated Integrin Activation and α-Granule Secretion Are Unaffected in Platelets Lacking p110α
To address the effects of p110α deletion on IGF-1-mediated potentiation of platelet function, we first established whether PAR4-AP-induced functional responses were altered in p110α KO platelets. Using flow cytometry to study the role of p110α in integrin activation and α-granule secretion, we observed that PAR4-AP stimulated a dose-dependent increase in PE-JON/A (phycoerythrin-JON/A) and fluorescein isothiocyanate-CD62P binding to mouse platelets, which was comparable between p110α KO and WT platelets ( Figure 3A and 3B). Similar results were found when platelets were stimulated with thrombin ( Figure 3C and 3D), the glycoprotein VI agonist CRP-XL (collagen-related peptide; Figure 3E and 3F), and the hemi-ITAM (immunostimulatory tyrosine activation motif)-containing receptor CLEC-2 (C-type lectin-like receptor 2) agonist fucoidan ( Figure 3G and 3H). These results illustrate that p110α deletion does not affect agonist-mediated activation of integrin α IIb β 3 or α-granule secretion.
IGF-1-Mediated Enhancement of Platelet Function Is Unaffected in Platelets Lacking p110α
Previous work has demonstrated an important role for p110α in IGF-1-mediated enhancement of human platelet function. 6, 7 Here, we find that IGF-1 also enhances functional responses of mouse platelets, with a significant increase in PAR4-AP-induced integrin α IIb β 3 activation and granule secretion ( Figure 4A and 4C) and collagen-mediated thrombus formation ( Figure 5 ). IGF-1 increased both the speed of platelet accumulation ( Figure 5B ) and the resultant area covered by thrombi and thrombus size ( Figure 5C ). Deletion of p110α had no effect on IGF-1-mediated increases in integrin α IIb β 3 activation and granule secretion ( Figure 4B and 4D) and thrombus formation ( Figure 5 ).
The p110β Inhibitor TGX-221 Ablates IGF-1-Mediated Akt Phosphorylation in p110α-Null Platelets
To examine why the results from p110α-deficient platelets differ from those reported using pharmacological agents, 6, 7 we determined the effects of a p110α-selective inhibitor (PIK-75 25, 26 ) and p110β isoform-specific inhibitor (TGX-221 17,26 ) on IGF-1-mediated Akt phosphorylation in mouse platelets. Pretreatment of WT platelets with an optimal concentration of PIK-75 (titrated using the p110α KO platelets- Figure I in the online-only Data Supplement) resulted in ≈50% loss of IGF-1-mediated Akt phosphorylation, which was comparable with Akt phosphorylation in p110α KO platelets ( Figure 6 ). At the dose used, PIK-75 had no effect on Akt phosphorylation in p110α KO platelets demonstrating minimal cross-reactivity of the inhibitor with other PI3K isoforms. Pretreatment of WT platelets with TGX-221 resulted in an ≈30% reduction of IGF-1-mediated Akt phosphorylation, whereas in p110α KO platelets a full ablation of Akt phosphorylation was observed. These results show that both p110α and p110β are involved in IGF-1-mediated phosphorylation of Akt, a result that is supported by the observation that dual treatment of WT platelets with PIK-75 and TGX-221 blocked Akt phosphorylation ( Figure 6 ).
Pharmacological Inhibition, But Not Deletion of p110α, Results in Loss of IGF-1-Mediated Platelet Priming
Considering the finding that IGF-1 requires both p110α and p110β for maximal Akt phosphorylation, it was important to evaluate their roles in IGF-1-mediated platelet priming. In support of previous findings, IGF-1-induced increases in PAR4-AP-mediated integrin activation and α-granule secretion were blocked by wortmannin, demonstrating that IGF-1 requires PI3K activation to enhance platelet function ( Figure 7A-7D ). Furthermore, in agreement with studies on human platelets, 6,7 PIK-75 blocked IGF-1-mediated potentiation of PAR4-AP-induced WT platelet activation ( Figure 7A and 7C). In contrast, IGF-1-mediated enhancement of integrin activation and α-granule secretion was intact in p110α KO platelets and was unaffected by PIK-75 ( Figure 7B and 7D) . The TGX-221 compound was able to reduce IGF-1-mediated platelet priming in WT platelets; however, this did not reach significance. In contrast, TGX-221 ablated IGF-1-mediated platelet priming in p110α KO platelets ( Figure 7A-7D) .
These results demonstrate that, under physiological circumstances, IGF-1-mediated platelet priming is driven primarily through the PI3K catalytic subunit p110α, with p110β likely to play a supportive role. However, in the physical absence of p110α, p110β is the primary driver of IGF-1-mediated platelet priming, demonstrating a degree of functional redundancy.
Akt-Independent Mechanism of IGF-1-Mediated Platelet Priming
As a result of the finding that IGF-1-mediated Akt phosphorylation was reduced in p110α-deficient platelets without a concurrent reduction in IGF-1-mediated platelet priming, we assessed the role of Akt in IGF-1-mediated increases in integrin activation and α-granule secretion. We previously showed that the allosteric Akt inhibitor MK-2206 (1 μmol/L) ablates thrombin-induced Akt phosphorylation in human and mouse platelets. 27 Here, we found that MK-2206 had no effect on PAR4-mediated integrin activation or α-granule secretion in both WT and p110α KO platelets (Figure 7) . IGF-1-mediated enhancement of platelet function was also unaffected by MK-2206 ( Figure 7 ), suggesting an Akt-independent mechanism of platelet priming.
Discussion
IGF-1 alone cannot induce platelet activation, but in combination with various physiological stimuli can enhance platelet functional responses. 6, 7 Because platelets play a critical role in hemostasis and have been implicated in the pathogenesis of cardiovascular disease, 23 altered levels of circulating primers such as IGF-1 may contribute to the mechanisms involved in this disease process. IGF-1 is also released from platelet α granules 1,2 after activation and can bind to IGF-1 or insulin/IGF-1 hybrid receptors expressed on the platelet plasma membrane with high affinity. 8, 9 This process helps modulate amplification of platelet responses and may further contribute to the development of cardiovascular disease. Pharmacological studies using the PIK-75 inhibitor suggested a role for PI3K p110α in IGF-1-mediated platelet priming. 6, 7 In the present study, we aimed to elucidate the role of p110α in IGF-1-mediated priming using a newly generated platelet-specific p110α KO murine model. This model allowed us to optimize the concentration of the dose whereby PIK-75 features as a p110α-selective inhibitor (titrated using the p110α KO platelets- Figure I in the online-only Data Supplement), given that it also targets other PI3K isoforms at higher concentrations. 25 Using these tools, we demonstrate that both p110α and p110β play a critical role in IGF-1-mediated Akt phosphorylation but that only p110α is required for IGF-1-mediated potentiation of platelet function. Interestingly, deletion of p110α did not affect IGF-1mediated potentiation of platelet function, suggesting that the physical absence of the p110α subunit allows this process to be mediated through p110β.
Binding of IGF-1 to the IGF-1 receptor induces transautophosphorylation of specific tyrosine residues and activation of the β subunits of the receptor. Subsequently, PI3K becomes catalytically active by binding to IRS proteins and triggers downstream phosphorylation of Akt. In our study, pretreatment of WT platelets with PIK-75 25, 26 and genetic deletion of p110α caused ≈50% reduction in IGF-1-mediated Akt phosphorylation. PIK-75 did not alter the Akt phosphorylation state achieved in KO platelets, demonstrating minimal cross-reactivity of the inhibitor with other PI3K isoforms. The p110β-selective ATP-competitive inhibitor TGX-221 26 blocked Akt phosphorylation in WT platelets treated with PIK-75 and in KO platelets, confirming that both p110α and p110β contribute to IGF-1-mediated Akt phosphorylation. This is in contrast to earlier findings on human platelets, where IGF-1-mediated Akt phosphorylation was solely dependent on p110α. 6, 7 The latter, however, may be explained by the use of a higher concentration of PIK-75 (500 versus 50 nmol/L in the present study), which is likely to inhibit both p110α and p110β ( Figure I in the online-only Data Supplement for mouse platelets). The finding that Akt phosphorylation was similar in WT platelets treated with PIK-75 and in p110α KO platelets demonstrated that p110β was unable to compensate for the loss in Akt phosphorylation in KO platelets.
PI3K plays a crucial role in platelet functional responses and platelet priming. 11, 12, 28 Despite our findings supporting a role for both p110α and p110β in IGF-1-mediated Akt phosphorylation, we found that PIK-75 alone blocked IGF-1-mediated priming in WT platelets. In agreement with previous studies, 6,7 these findings demonstrate that under physiological conditions IGF-1-mediated platelet priming is driven primarily through the p110α isoform. Surprisingly, IGF-1-mediated priming was unaffected in KO platelets and blocked by the p110β inhibitor TGX-221. This discrepancy in results is likely to be explained by the physical presence/ absence of the p110α subunit under different conditions. In WT platelets, the p110α proteins can still associate with IRS proteins via their p85 regulatory subunit after IGF-1 stimulation, thus titrating out the effects of p110β. In contrast, the KO platelets do not express p110α; therefore, p110β does not have to compete for recruitment to receptors. A similar mechanism of compensation between p110α and p110β has previously been described in myoblasts. 29 Of note is, however, that we found no compensation in Akt phosphorylation in the p110α KO mice, suggesting that if this process happens, it may be restricted to subareas in the cell that do not link to Akt phosphorylation. The lack of association of Akt phosphorylation and potentiating effect of IGF-1 suggests that Akt may not be involved in platelet priming downstream of PI3K. This is supported by our findings that IGF-1-mediated enhancement of platelet function is unaffected by the allosteric Akt inhibitor, MK-2206. An alternative explanation for the lack of a phenotype in p110α-deficient platelets may be that the p110α subunit itself negatively regulates platelet priming in a lipid kinase-independent negative feedback manner. The absence of p110α would then allow p110β to drive potentiation of platelet function. Lipid kinase-independent roles have recently been described for p110β and p110δ in insulin signaling and cell survival, respectively. 30, 31 
Conclusions
In conclusion, we demonstrate that IGF-1-mediated Akt phosphorylation is mediated by both p110α and p110β but that p110α is the critical PI3K isoform driving IGF-1-mediated platelet priming. In the absence of the p110α isoform, this role can be taken over by the p110β isoform.
Platelets are anuclear secretory cells that are important in primary hemostasis but also play a critical role in causing arterial thrombosis, a major factor contributing to heart attacks and strokes. Platelet primers such as insulin-like growth factor-1 contribute to thrombosis by increasing platelet responses through activation of the lipid kinase, phosphoinositide 3-kinase. Here, we demonstrate that both the phosphoinositide 3-kinase p110α and p110β isoforms contribute to insulin-like growth factor-1-mediated Akt phosphorylation but that only p110α is essential for insulin-like growth factor-1-mediated priming of platelet function. Genetic deletion of p110α leads to compensation by p110β in priming platelet function by insulin-like growth factor-1.
Significance
